11
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      United States internet searches for “infertility” following COVID-19 vaccine misinformation

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Context

          On December 1, 2020, Drs. Wolfgang Wodarg and Michael Yeadon petitioned to withhold emergency use authorization of the BNT162b2 messenger ribonucleic acid vaccine for coronavirus disease 2019 (COVID-19) manufactured by BioNTech and Pfizer, raising concern for female infertility risks but acknowledging the lack of evidence. The European Medicines Agency and the US Food and Drug Administration ultimately issued emergency use authorizations, but misinformation claiming that COVID-19 vaccines cause female infertility began circulating on social media, potentially influencing public perception and medical decision making among pregnant patients or those seeking to become pregnant.

          Objectives

          To determine the potential influence misinformation may have had on public interest in infertility related topics, as analyzed through internet search statistics in the US.

          Methods

          The Google Trends tool was used to analyze results for the search terms “infertility,” “infertility AND vaccine,” and “infertility AND COVID vaccine” in the US from February 4, 2020 to February 3, 2021. We applied autoregressive integrated moving average models to forecast expected values, comparing them with actual observed values.

          Results

          At peak interest (100), the forecasted relative search volumes interest for the search terms “infertility,” “infertility AND vaccine,” and “infertility AND COVID vaccine” were 45.47 (95% CI, 33.27–57.66; p<0.001), 0.88 (95% CI, 2.87–4.63; p<0.001), and 0.29 (95% CI, −2.25–2.82; p<0.001). The actual relative search volumes at peak searching represented 119.9, 11,251, and 34,900% increases, respectively, when compared with forecasted values.

          Conclusions

          COVID-19 vaccine misinformation corresponded with increased internet searches for topics related to infertility in the US. Dispelling misinformation and informing patients about the risks and benefits of COVID-19 vaccination may prevent unnecessary vaccine hesitancy or refusal, contributing to successful vaccination efforts.

          Related collections

          Most cited references5

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Demographic Characteristics of Persons Vaccinated During the First Month of the COVID-19 Vaccination Program — United States, December 14, 2020–January 14, 2021

          In December 2020, two COVID-19 vaccines (Pfizer-BioNTech and Moderna) were authorized for emergency use in the United States for the prevention of coronavirus disease 2019 (COVID-19).* Because of limited initial vaccine supply, the Advisory Committee on Immunization Practices (ACIP) prioritized vaccination of health care personnel † and residents and staff members of long-term care facilities (LTCF) during the first phase of the U.S. COVID-19 vaccination program ( 1 ). Both vaccines require 2 doses to complete the series. Data on vaccines administered during December 14, 2020–January 14, 2021, and reported to CDC by January 26, 2021, were analyzed to describe demographic characteristics, including sex, age, and race/ethnicity, of persons who received ≥1 dose of COVID-19 vaccine (i.e., initiated vaccination). During this period, 12,928,749 persons in the United States in 64 jurisdictions and five federal entities § initiated COVID-19 vaccination. Data on sex were reported for 97.0%, age for 99.9%, and race/ethnicity for 51.9% of vaccine recipients. Among persons who received the first vaccine dose and had reported demographic data, 63.0% were women, 55.0% were aged ≥50 years, and 60.4% were non-Hispanic White (White). More complete reporting of race and ethnicity data at the provider and jurisdictional levels is critical to ensure rapid detection of and response to potential disparities in COVID-19 vaccination. As the U.S. COVID-19 vaccination program expands, public health officials should ensure that vaccine is administered efficiently and equitably within each successive vaccination priority category, especially among those at highest risk for infection and severe adverse health outcomes, many of whom are non-Hispanic Black (Black), non-Hispanic American Indian/Alaska Native (AI/AN), and Hispanic persons ( 2 , 3 ). Data on COVID-19 vaccine doses administered in the United States are collected by vaccination providers and reported to CDC through multiple sources, including jurisdictions, pharmacies, and federal entities, who use various reporting methods including immunization information systems, ¶ Vaccine Administration Management System,** and direct data submission. Data on first vaccine doses administered during December 14, 2020–January 14, 2021, and reported to CDC by January 26, 2021, were analyzed to describe demographic characteristics, including sex, age, and race/ethnicity among persons who received ≥1 dose of COVID-19 vaccine. Age was calculated based on date or year of birth and date of vaccine administration and was categorized as 120 years) were treated as unknown, which represented <0.1% of persons initiating vaccination. ¶ Race/ethnicity was not reported or was unknown for all persons initiating vaccination in six jurisdictions. The six jurisdictions not reporting race/ethnicity have a total population of approximately 18.9 million, which represents nearly 6% of the overall U.S. population. ** Represents persons identified as being non-Hispanic and having multiple race categories selected or being non-Hispanic and having “other race” selected. Discussion During the first month of the U.S. COVID-19 vaccination program, 12,928,749 persons received ≥1 dose of COVID-19 vaccine, representing approximately 4% of the total U.S. population and 5% of the U.S. population aged ≥16 years.*** If vaccination was only provided to persons in the Phase 1a priority groups (health care personnel and LTCF residents), coverage among the 24 million persons included in these groups might have been as high as 50% ( 1 ). However, this is likely an overestimate because persons outside of the 1a priority group were vaccinated because of variation in implementation of national guidance at the jurisdictional and local levels (e.g., Florida and Texas expanded vaccination to all persons aged ≥65 years). ††† Among persons who received the first vaccine dose and had available data for the respective demographic characteristic variable, 63.0% were women, 55.0% were aged ≥50 years, and 60.4% were White, which likely reflects the demographic characteristics of the persons (health care personnel and LTCF residents) recommended to be vaccinated in the Phase 1a priority group ( 4 , 5 ). Data from the 2019 American Community Survey show that 60% of health care workers were White, 16% were Black, 13% were Hispanic, and 7% were Asian; however, race and ethnicity varied widely by occupation and setting ( 6 ). Women also account for approximately three fourths of persons employed in the health care industry ( 7 ). In addition, the 2015–2016 National Study of Long-Term Care Providers found that 65% of nursing home residents were women, 75% were White, 14% were Black, and 5% were Hispanic ( 8 ). Interpretation of data from the analysis of COVID-19 vaccination initiation is limited by the high percentage of records with unknown or missing race/ethnicity information and the unknown proportions of priority groups (health care personnel versus LTCF residents) among early vaccine recipients. Differences in how race and ethnicity data are collected and categorized, for example 14.4% of persons initiating vaccination reported as multiple or other race/ethnicity, also make comparisons difficult. The percentage of persons initiating vaccination who were Black appears lower relative to the percentage of persons who are Black among health care personnel and LTCF residents. Overall, 39.6% of persons who were vaccinated represented racial and ethnic minorities. Because persons who are Black, AI/AN, or Hispanic have been found to have more severe outcomes from COVID-19 than persons who are White, careful monitoring of vaccination by race/ethnicity is critical ( 2 , 9 ). The findings in this report are subject to at least three limitations. First, race/ethnicity was unknown for approximately one half of the population who initiated vaccination during the first month of the COVID-19 vaccination program in the United States. In addition, the proportion of persons with unknown race/ethnicity varied across jurisdictions, including six jurisdictions that reported no race/ethnicity data. §§§ In addition, a high proportion of persons receiving vaccination were categorized as non-Hispanic, multiple or other races, whereas the population estimates from the 2019 American Community Survey ¶¶¶ 1-year population were 2.8% non-Hispanic, multiple or other races. Thus, the findings presented in this study might not be generalizable to all persons initiating COVID-19 vaccination in the United States. The large proportion of missing data also might result in biased estimates of race/ethnicity, particularly if some groups are more likely than others to have race/ethnicity reported as unknown. Second, vaccine administration data reported to CDC include limited data elements and did not allow for stratification by the prioritized populations (health care personnel and LTCF residents) in the initial phase of the vaccination campaign. Therefore, it was not possible to directly compare the observed demographic patterns among persons initiating vaccination to demographic characteristics of prioritized populations. Finally, implementation of the ACIP recommendations, including subprioritization, varied by jurisdiction, with some jurisdictions changing and expanding their priority populations during the first month of the vaccination program. Although these data reflect characteristics of persons initiating vaccination during the initial phase of the U.S. COVID-19 vaccination program and have several limitations, the findings underscore the need for more complete reporting of race and ethnicity data at the provider and jurisdictional levels to ensure rapid detection of and response to potential disparities in COVID-19 vaccine administration. Jurisdictions should monitor the demographic characteristics of vaccinated persons to identify emerging disparities. In addition, as vaccination expands to include additional groups, monitoring coverage by the Social Vulnerability Index, which uses U.S. Census Bureau variables to identify communities that might need support, will be useful to ensure equity and to identify communities where focused immunization efforts might be required.**** CDC is working with jurisdictions to use these types of analyses to help direct efforts to bring vaccines to their communities and ensure that no persons are left behind. These data from the first month of the COVID-19 vaccination program indicate substantial progress in administration of the COVID-19 vaccine. To increase coverage among persons in Phase 1a, as vaccination expands into additional populations, unvaccinated health care personnel and LTCF residents should continue to be offered COVID-19 vaccine. Equitable and sustainable COVID-19 vaccine administration in all populations requires focus on groups with lower vaccine receipt who might face challenges with access or vaccine hesitancy. Summary What is already known about this topic? In December 2020, two COVID-19 vaccines were authorized for emergency use in the United States. The first groups prioritized for vaccination included health care personnel and long-term care facility residents. What is added by this report? During the first month of the U.S. COVID-19 vaccination program, approximately 13,000,000 persons received ≥1 dose of vaccine. Among persons with demographic data, 63.0% were women, 55.0% were aged ≥50 years, and 60.4% were non-Hispanic White. What are the implications for public health practice? As the vaccination program expands, it is critical to ensure efficient and equitable administration to persons in each successive vaccine priority category, especially those at highest risk for infection and severe health outcomes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Gender Differences in Health Care Expenditures, Resource Utilization, and Quality of Care

            Gary Owens (2008)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              A Message from the Human Placenta: Structural and Immunomodulatory Defense against SARS-CoV-2

              The outbreak of the coronavirus disease 2019 (COVID-19) pandemic has caused a global public health crisis. Viral infections may predispose pregnant women to a higher rate of pregnancy complications, including preterm births, miscarriage and stillbirth. Despite reports of neonatal COVID-19, definitive proof of vertical transmission is still lacking. In this review, we summarize studies regarding the potential evidence for transplacental transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), characterize the expression of its receptors and proteases, describe the placental pathology and analyze virus-host interactions at the maternal-fetal interface. We focus on the syncytium, the barrier between mother and fetus, and describe in detail its physical and structural defense against viral infections. We further discuss the potential molecular mechanisms, whereby the placenta serves as a defense front against pathogens by regulating the interferon type III signaling, microRNA-triggered autophagy and the nuclear factor-κB pathway. Based on these data, we conclude that vertical transmission may occur but rare, ascribed to the potent physical barrier, the fine-regulated placental immune defense and modulation strategies. Particularly, immunomodulatory mechanisms employed by the placenta may mitigate violent immune response, maybe soften cytokine storm tightly associated with severely ill COVID-19 patients, possibly minimizing cell and tissue damages, and potentially reducing SARS-CoV-2 transmission.
                Bookmark

                Author and article information

                Contributors
                (View ORCID Profile)
                (View ORCID Profile)
                Journal
                Journal of Osteopathic Medicine
                Walter de Gruyter GmbH
                2702-3648
                May 25 2021
                May 07 2021
                June 01 2021
                May 25 2021
                April 12 2021
                June 01 2021
                : 121
                : 6
                : 583-587
                Affiliations
                [1 ]Office of Medical Student Research, Oklahoma State University Center for Health Sciences , Tulsa , OK , USA
                [2 ]Department of Obstetrics & Gynecology , Ascension Oklahoma St. John Medical Center , Tulsa , OK , USA
                [3 ]Department of Psychiatry and Behavioral Sciences , Oklahoma State University Center for Health Sciences , Tulsa , OK , USA
                Article
                10.1515/jom-2021-0059
                33838086
                2c69209c-ef00-40cf-a6e1-48ed785ee53f
                © 2021

                http://creativecommons.org/licenses/by/4.0

                History

                Comments

                Comment on this article